Provider review
Found review: pricing, pharmacy, and evidence status
Released: · Last reviewed: · By Dr. Parmis
Found offers GLP-1 medications through telehealth. Every price, credential and pharmacy claim below is labeled by evidence status and read date.
Found's lowest price on file is $149/month (12-month term, per 28-day cycle (cash pay)), read November 20, 2026 on its own page. It does not name a dispensing pharmacy. On November 20, 2026 it scored 80.8/100 on GLP Ranked's v4.1 rubric, #4 of 15.
Rank and score
Found scores 80.8 of 100, #4 of 15 scored programs (November 20, 2026). The table shows every sub-check, the points earned and why; the methodology explains each one.
| ID | Category | Sub-check | Points | Note |
|---|---|---|---|---|
| PT1 | Pricing transparency | Drug price printed on the program's own page, read in the November 20, 2026 re-read | 5 of 5 | |
| PT2 | Pricing transparency | Price includes medication and care, or every required fee is printed beside it (2 if the program's own figures disagree) | 5 of 5 | |
| PT3 | Pricing transparency | Price at every dose knowable: same price at every dose, or a full dose ladder | 5 of 5 | 'Same price every dose' on its tirzepatide page |
| PT4 | Pricing transparency | Plan term and billing interval stated (2 if the program's own pages disagree) | 5 of 5 | |
| CO1 | Clinical oversight | Prescribing medical group named (9), network label (5), physician executive only (3), arrangement described (2) | 9 of 9 | |
| CO2 | Clinical oversight | Prescribers' licensure or certification stated | 3 of 3 | |
| CO3 | Clinical oversight | Clinical lead (medical director or chief medical officer) named with credential | 0 of 3 | |
| PH1 | Pharmacy transparency | Dispensing pharmacy named (10), class described but not named (4), described only (2); brand-only programs whose pages say prescriptions go to the pharmacy you choose (10) | 4 of 10 | 'licensed 503A compounding pharmacies', none named |
| PH2 | Pharmacy transparency | Pharmacy class (503A/503B) or licensure stated; brand-only programs that send prescriptions to your chosen pharmacy (5) | 5 of 5 | |
| SU1 | Support | Two or more contact channels published (4), one (2) | 4 of 4 | |
| SU2 | Support | How to cancel is stated | 3 of 3 | |
| SU3 | Support | Refund terms are stated (any stated condition under which money is refunded or credited) | 3 of 3 | |
| RD1 | Regulatory disclosure | Compounded products described as not FDA-approved; brand-only programs (5) | 5 of 5 | |
| RD2 | Regulatory disclosure | No open FDA warning letter in FDA's index (read November 20, 2026) | 5 of 5 | |
| AC1 | Accessibility | Where it operates stated clearly (4); vague or conflicting statements (2) | 2 of 4 | 'not available in all states' |
| AC2 | Accessibility | Payment beyond a card stated (HSA/FSA or pay-later) | 3 of 3 | |
| AC3 | Accessibility | Can start month to month without a multi-month commitment | 3 of 3 | |
| AN | Total annual cost | semaglutide, 12 months: $1,937 (12-month term: 13 × $149 per 28-day cycle); benchmark $1,140 | 11.8 of 20 | 20 × benchmark ÷ cost |
| Total | 80.8 of 100 | |||
Strengths and limitations
Drawn from the sub-checks above, as read November 20-21, 2026.
- Strength: Drug price printed on the program's own page, read in the November 20, 2026 re-read.
- Strength: Price includes medication and care, or every required fee is printed beside it.
- Strength: Price at every dose knowable: same price at every dose, or a full dose ladder.
- Strength: Plan term and billing interval stated.
- Limitation: Clinical lead: 0 of 3.
- Limitation: Dispensing pharmacy named: 4 of 10 ('licensed 503A compounding pharmacies', none named).
- Limitation: Where it operates stated clearly: 2 of 4 ('not available in all states').
- Limitation: total annual cost scores 11.8 of 20.
Pricing by plan
| Medication | Formulation | Plan | Price | Source | Evidence |
|---|---|---|---|---|---|
| tirzepatide | compounded injectable | Month to month, per 28-day cycle (cash pay) | $339/mo | provider page · read 2026-11-20 | Provider reported |
| tirzepatide | compounded injectable | 12-month term, per 28-day cycle (cash pay) | $199/mo | provider page · read 2026-11-20 | Provider reported |
| semaglutide | compounded injectable | Month to month, per 28-day cycle (cash pay) | $269/mo | provider page · read 2026-11-20 | Provider reported |
| semaglutide | compounded injectable | 12-month term, per 28-day cycle (cash pay) | $149/mo | provider page · read 2026-11-20 | Provider reported |
"Provider reported" means the figure comes from the company's own site or intake flow and has not been independently corroborated by GLP Ranked.
Clinical model
Professional corporations: “As part of offering the Services, Found Health, Inc. contracts with Pippen Health of California, P.C., Pippen Health of Texas, P.A., Pippen Health of Delaware, P.A., Pippen Health of New Jersey, P.A., Cloud Health Medical Group, P.A., Cloud Health Medical Grou…” (joinfound.com, read 2026-11-10)
Prescribing entity named: Pippen Health of California, P.C.; of Texas, P.A.; of Delaware, P.A.; of New Jersey, P.A.; Cloud Health Medical Group, P.A.; of California, P.C.; of New Jersey, P.A.; of Kansas, P.C.; Adept Labs, Inc. d/b/a Vital and its affiliate Openloop Healthcare Partners, PC.
Accreditation: we have not verified any accreditation or certification claim for Found against the issuing body. If a program cites one (for example LegitScript), check the issuer's public lookup before you rely on it.
Pharmacy & compliance
Says it "partners exclusively with 503A-licensed pharmacies"; pharmacy not named (read 2026-11-10) Pharmacy transparency is worth 15 of 100 points under our v4.1 rubric.
State availability
State-by-state availability is not independently verified.
Who this suits — and who it doesn't
Found may suit patients who want a standard-dose program and are comfortable proceeding without a named dispensing pharmacy disclosed up front.It is a weaker fit for patients who need written proof of pharmacy accreditation before paying; ask the company for it.
Terms to check before you pay: whether cancellation and refund terms were found on its pages is recorded in sub-checks SU2 and SU3 above (read November 21, 2026); published support response times: not published.
Sources
- FDA: Warning letters index (searched for this program) — Regulator database, captured 2026-11-20
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current October 1, 2026) — Regulator page, captured 2026-11-20
- FDA: Compounding: Inspections, Recalls, and other Actions (content current October 22, 2026) — Regulator list, captured 2026-11-21
Cite this page
GLP Ranked. "Found review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/found/
GLP Ranked. "Found review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/found/